The splicing factor kinase SRPK1 is a therapeutic target for Peripheral Vascular Disease
S. R. Bhalla, M. Wahid, J. Amartey, A. Zawia, F. Riu, Y. Gao, J. Agrawal, A. P. Lynch, M. J. Machado, T. Hawtrey, R. Kikuchi, K. R. Green, L. Teboul, C. Allen, Z. Blackley, , D. O. Bates
This paper shows that inhibiting SRPK1 in monocytes promotes angiogenesis by altering VEGF splicing from anti-angiogenic VEGF-A165b to pro-angiogenic VEGF-A165a in both human and mouse models of peripheral arterial disease.
bioRxiv · Apr 17, 2024Physiology